NCR-101
- Generic Name
- NCR-101
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease
Phase 1
Not yet recruiting
- Conditions
- Interstitial Lung Disease (ILD)
- Interventions
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Nuwacell Biotechnologies Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06825169
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath